



MsNRAMP2	MSGPSREDNSKEVREEDENRRLLEWDGEEGDSDISDEEAAMESGERIVVWDEFG..IVDDSTIIPFFSWKWLFIGPG	78
MtNRAMP2	MSGPSREDNSKEVREEDENRRLLEVNVEGE..SSSPDEAAAMESGERIVVWDEFG..IVDDSTIIPFFSWKWLFIGPG	76
AtNRAMP2	....MENURKENIEEEEDRILIFPPPSQSLFSTDSESEAARPTNEKILLIVDFESPDDFTTIDIPFFSWKWLFIGPG	75
Consensus	e ke ee se eaa e eki vdfe t ppfsw klw ftgpg	
MsNRAMP2	FIMSIATFLDPGNLFGDIQAGAIAGYSLLWLMWATMLGLLIQSLSARVGVATGRHLAEELCRLEYEYHWWARYVLWMAELAL	158
MtNRAMP2	FIMSIATFLDPGNLLEGDLQAGAIAGYSLLWLMWATMLGLLIQSLSARVGVATGRHLAEELCRLEYEYHWWARYVLWMAELAL	156
AtNRAMP2	FIMSIATFLDPGNLLEGDLQAGAIAGYSLLWLMWATMLGLLIQSLSARVGVATGRHLAEELCRLEYEYHWWARYVLWMAELAL	155
Consensus	fim s i a f l d p g n l e g d l q a g a i a g y s l l w l l m w a t m g l l i q l s a r v g v a t g r h l a e l c e y p w a r y v l w m a e l a l	
MsNRAMP2	IGADIQEVIGSAIAIQILSRQGLPLIWAGVLITASDCFELFLFLENYGVRKLEAFAVLIATMILSFIAWMFGDAAPSGKELIV	238
MtNRAMP2	IGADIQEVIGSAIAIQILSRQGLPLIWAGVLITASDCFELFLFLENYGVRKLEAFAVLIATMILSFIAWMFGDAAPSGKELIV	236
AtNRAMP2	IGADIQEVIGSAIAIQILSRQGLPLIWAGVLITASDCFELFLFLENYGVRKLEAFAVLIATMILSFIAWMFGDAAPSGKELIV	235
Consensus	igadiqevigsaiaiqilsrq lplwagy itasdclf flflenygvrkleafavliatm lsfawmfg psgkel	
MsNRAMP2	EGILIPRRESSKTIHQAVGVVGCVIMPHNVFLHSALVQSRKIDEHPRERVQEALNNYIESVALSVFMINLFVITVFAK	318
MtNRAMP2	EGILIPRRESSKTIHQAVGVVGCVIMPHNVFLHSALVQSRKIDEHPRERVQEALNNYIESVALSVFMINLFVITVFAK	316
AtNRAMP2	EGILIPRRESSKTIHQAVGVVGCVIMPHNVFLHSALVQSRKIDEHPRERVQEALNNYIESVALSVFMINLFVITVFAK	315
Consensus	gil pr sskti qavgvvvcimphnvlhsalvqsrkdp k rvqealnny ies val fminlfvttvfak	
MsNRAMP2	GFYGTWKANSIGLVNAGQYLPEKYGGLDFPILYIWGILLRAAGGSSTITGTYAGQFIMGGFLNIRLKKWRADITRSCAI	398
MtNRAMP2	GFYGTWKANSIGLVNAGQYLPEKYGGLDFPILYIWGILLRAAGGSSTITGTYAGQFIMGGFLNIRLKKWRADITRSCAI	396
AtNRAMP2	GFYGTWKANSIGLVNAGQYLPEKYGGLDFPILYIWGILLRAAGGSSTITGTYAGQFIMGGFLNIRLKKWRADITRSCAI	395
Consensus	gfygt an iglvnaggyl ek gggl pilyiwgillraaggssttigtgyaggfimggflnlrlkkw ra itrscai	
MsNRAMP2	VFTIIVAIWNSEASLDVNLNEWLNVLQSICQIFFALPLITLVSKEPIMGSFKVGEVLRPAWTVAALIIINGYLIVDF	478
MtNRAMP2	VFTIIVAIWNSEASLDVNLNEWLNVLQSICQIFFALPLITLVSKEPIMGSFKVGEVLRPAWTVAALIIINGYLIVDF	476
AtNRAMP2	VFTIIVAIWNSEASLDVNLNEWLNVLQSICQIFFALPLITLVSKEPIMGSFKVGEVLRPAWTVAALIIINGYLIVDF	475
Consensus	vpt i v a i v n s e a s l d v n l e w l n v l q s q i p f a l p l l t l v s k e img fk gp l r a w t v a a l i n g y l l d f	
MsNRAMP2	EISEVNSVLFGFVACSCIVAYIAFIVYLISLSGAIPPSALVDR...LPKGFCSE	529
MtNRAMP2	EISEVNSVLFGFVACSCIVAYIAFIVYLISLSGAIPPSALVDR...LPKGFCSE	527
AtNRAMP2	EISEVDSFLFGTVQWTTIYIAFIVYLISLSNFPSWSSSSIELPKRVSVEN	529
Consensus	f sev lfg c t yiafivylis s ps lpk s	

**Figure S1.** MsNRAMP2, MtNRAMP2(XM\_013606289.3) and AtNRAMP2(NM\_103618.3) amino acid sequence alignment.



**Figure S2.** MsNRAMP2 transgenic tobacco: (a) Germination of MsNRAMP2 overexpression transgenic tobacco; (b) Screening and culture of MsNRAMP2 transgenic tobacco; (c) MsNRAMP2 transgenic tobacco positive plant.



**Figure S3.** PCR amplification of *MsMYB* CDS fragment: M: DL2000 Marker; 1: *MsMYB* fragment.